

2/10/99

510(k) Premarket Notification  
K984262 (Previously K973721)  
BIONECT® Hydrogel Gauze Pads

**fidia** Pharmaceutical Corporation

February 1, 1999

**10. 510(k) SUMMARY**

**10.1 Summary Information**

**10.1.1 Submitter's name and address**

FIDIA Pharmaceutical Corporation  
2000 K Street, NW, Suite 700  
Washington, DC 20006

Contact person and telephone number:

Roberto Fiorentini, M.D., President

Telephone: (202) 371-1325

Telefax: (202) 371-1666

Date summary was prepared:

February 1, 1999

**10.1.2 Name of the Device**

Trade Name: BIONECT® Hydrogel Gauze Pads

Common Name: Hyaluronic acid sodium salt hydrogel dressing-impregnated gauze pads

Classification Name: Hydrogel Wound and Burn Dressing

510(k) Premarket Notification  
K984262 (Previously K973721)  
BIONECT® Hydrogel Gauze Pads

**fidia** Pharmaceutical Corporation

February 1, 1999

**10.1.3 Identification of predicate device to which substantial equivalence is being claimed**

BIONECT® Hydrogel Gauze Pads are substantially equivalent in function and intended use to the following cleared non-interactive wound and burn dressing: BIONECT® Hydrogel.

**10.1.4 Device description**

Explanation of how the device functions: BIONECT® Hydrogel Gauze Pads, since they contain a hydrogel, provide a moist wound environment that is supportive to wound healing.

Basic scientific concepts that form the basis for the device: BIONECT® Hydrogel Gauze Pads, since they are a hydrogel dressing, were designed to provide a soothing, moist environment that is supportive to wound healing.

Significant physical and performance characteristics of the device such as device design, materials used, and physical properties: BIONECT® Hydrogel Gauze Pads are sterile cotton gauze pads impregnated with a hydrogel that is prepared from sodium hyaluronate and purified water to form a hydrogel dressing. Sodium hyaluronate is a polysaccharide biopolymer that can increase the viscosity of the gel. BIONECT® Hydrogel Gauze Pads, since they are a hydrogel dressing, provide a soothing, moist environment that is supportive to wound healing

**10.1.5 Statement of the intended use of the device, including general description of the conditions the device will mitigate and the patient population for which the device is intended**

K984262

510(k) Premarket Notification  
K984262 (Previously K973721)  
BIONECT® Hydrogel Gauze Pads

February 1, 1999

**fidia** Pharmaceutical Corporation

**10.1.5 Statement of the intended use of the device, including general description of the conditions the device will mitigate and the patient population for which the device is intended**

BIONECT® Hydrogel Gauze Pads provide a moist wound environment that is supportive to wound healing. They are indicated for the dressing and management of minor burns; superficial cuts, lacerations, and abrasions; and minor irritations of the skin. A health care professional may be consulted prior to the first use of this product to determine whether these conditions exist. BIONECT® Hydrogel Gauze Pads may also be used under the care of a health care professional for wounds such as partial to full thickness dermal ulcers (pressure ulcers, venous stasis ulcers, arterial ulcers, diabetic ulcers), surgical wounds (post-operative incisions and donor sites), and second degree burns.

These indication statements are not different from the predicate device identified in paragraph (3) of this section.

**10.1.6 Statement of how the technological characteristics of the device compare to those of the predicate device**

The technological characteristics of the device such as form, occlusion, conformability, bioburden level, moist wound healing, and appearance in the wound when hydrated are not different from the predicate devices cited.

**10.2 Assessment of performance data**

*In vitro* and *in vivo* biocompatibility testing (cytotoxicity, dermal irritation, and dermal sensitization tests) has been performed on the bulk solution that impregnates BIONECT®

510(k) Premarket Notification  
K984262 (Previously K973721)  
BIONECT® Hydrogel Gauze Pads

**fidia** Pharmaceutical Corporation

February 1, 1999

safe use of BIONECT® Hydrogel Gauze Pads as a hydrogel temporary dressing in contact with breached or compromised skin.

Clinical experience with BIONECT® Hydrogel Gauze Pads in approximately 430 patients with various types of ulcers and burns in 16 clinical trials (13 controlled), indicates that BIONECT® Hydrogel Gauze Pads are safe for their intended use.



FEB 10 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Roberto Fiorentini  
President  
Fidia Pharmaceutical Corp.  
2000 K Street, N.W. - Suite 700  
Washington, D.C. 20006

Re: K984262-BIONECT Hydrogel Gauze Pads  
K984264-BIONECT Clear Hydrogel  
K984266-BIONECT Hydrogel Spray  
K984267-BIONECT Hydrogel Foam  
K984413-BIONECT Hydrogel

Regulatory Class: Unclassified

Product Code: MGQ

Dated: November 17, 1998

Received: November 17, 1998

Dear Mr. Fiorentini:

We have reviewed your Section 510(k) notifications of intent to market the devices referenced above and we have determined the devices are substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market your devices subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations:

1. These devices may not be labeled for use on third degree burns.
2. These devices may not be labeled as having any accelerating effect on the rate of wound healing or epithelization.
3. These devices may not be labeled as a long-term, permanent, or no-change dressing, or as an artificial (synthetic) skin.
4. These devices may not be labeled as a treatment or a cure for any type of wound.

The labeling claims listed above would be considered a major modification in the intended use of the devices and would require a premarket notification submission (21 CFR 807.81).


The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.

If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your devices can be found in the Code of Federal Regulations (CFR), Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practices (GMP) for Medical Devices: General GMP regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your devices in the Federal Register. Please note: this response to your premarket notification submissions does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your devices as described in your 510(k) premarket notifications. The FDA finding of substantial equivalence of your devices to a legally marketed predicate device results in a classification for your devices and thus, permits your devices to proceed to the market.

If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or 301-443-6597 or at its internet address <http://www.fda.gov/cdrh/dsmamain.html>.

Sincerely yours,



*Celia M. Witten*

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General and  
Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**fidia** Pharmaceutical Corporation

February 1, 1999

**2. INDICATIONS FOR USE**

510(k) Number (if known): K984413 (Previously K963004)  
K984262 (Previously K973721)  
K984267 (Previously K973722)  
K984266 (Previously K973725)  
K984264 (Previously K973725)

Device Name: BIONECT® Hydrogel  
BIONECT® Hydrogel Gauze Pads  
BIONECT® Hydrogel Foam  
BIONECT® Hydrogel Spray  
BIONECT® Clear Hydrogel

Indications for Use:


BIONECT® Hydrogel, Gauze Pads, Foam, Spray, and Clear Hydrogel are indicated for the dressing and management of minor burns; superficial cuts, lacerations, and abrasions; and minor irritations of the skin. A health care professional may be consulted prior to the first use of these products to determine whether these conditions exist. BIONECT® Hydrogel, Gauze Pads, Foam, Spray, and Clear Hydrogel may also be used under the care of a health care professional for wounds such as partial to full thickness dermal ulcers (pressure ulcers, venous stasis ulcers, arterial ulcers, diabetic ulcers), surgical wounds (post-operative incisions and donor sites), and second degree burns.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use \_\_\_\_\_  
(Per 21 CFR 801.109)

or

Over-the Counter Use X



2

(Division Sign-Off)  
Division of General Restorative Devices  
510(k) Number \_\_\_\_\_

K984262, K984264, K984266,  
K984267, K984413